Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.
The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Results of an online survey evaluating the experiences and preferences of patients with metastatic breast cancer were reported.
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Researchers present data on use of palliative care in the last 30 days of life and the impact on costs among those who did and did not receive palliative care.
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
Results of a multicenter study reveal differences in genetic testing in patients with prostate cancer who meet NCCN guidelines compared with those who do not.
